AbbVie (ABBV) Net Cash Flow (QoQ) (2012 - 2026)
Powered by 
Analysis
AbbVie (ABBV) Net Cash Flow (QoQ) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -167.44% |
| Mar 31, 2026 | 1,115.57% |
| Dec 31, 2025 | 50.48% |
| Sep 30, 2025 | -165.77% |
| Jun 30, 2025 | 452.51% |
| Mar 31, 2025 | 78.78% |
| Dec 31, 2024 | 71.31% |
| Sep 30, 2024 | -19.34% |
| Jun 30, 2024 | -193.49% |
| Mar 31, 2024 | 1,162.70% |
| Dec 31, 2023 | -110.92% |
| Sep 30, 2023 | 120.80% |
| Jun 30, 2023 | 182.39% |
| Mar 31, 2023 | 5.88% |
| Dec 31, 2022 | -178.75% |
| Sep 30, 2022 | 37.21% |
| Jun 30, 2022 | 167.20% |
| Mar 31, 2022 | -51.79% |
| Dec 31, 2021 | -165.49% |
| Sep 30, 2021 | 397.49% |